Systematic (IUPAC) name | |
---|---|
[(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone | |
Clinical data | |
Pregnancy cat. | ? |
Legal status | ? |
Identifiers | |
CAS number | 1030377-33-3 |
ATC code | ? |
PubChem | CID 24965990 |
Chemical data | |
Formula | C23H23ClN6O2 |
Mol. mass | 450.920 g/mol (free base) |
SMILES | eMolecules & PubChem |
(verify) |
(what is this?)
Suvorexant (MK-4305) is an orexin receptor antagonist in development by Merck & Co.[1][2][3] This drug for sleep disorders has passed Phase II trials, and is one of several such compounds currently in development, the others being Actelion's ACT-078573 and GlaxoSmithKline's SB-649,868.
|